Orforglipron
授权管线 · 口服片剂 · 12 mg / 24 mg / 36 mg
授权管线US DMF II（在编）Confidentiality：高保密
- INN / Generic Name
- Orforglipron
- Dosage Form
- 口服片剂
- Strength
- 12 mg / 24 mg / 36 mg
- Therapy Area
- GLP-1（代谢）
- Indication
- 2 型糖尿病 / 肥胖症（口服小分子 GLP-1RA）
- Current Status
- 临床 III 期；仿制供应链布局中
- GMP Certification
- cGMP（自有基地）
- CEP
- No
- DMF Type
- US DMF II（在编）
- Stability Data
- 18 months
- BE Required
- Yes
- Registration Pathway
- NP（专利期后）/ 自愿许可路径
- MOQ
- 1 个项目
- Lead Time
- 210 天
- Price Range
- 授权 upfront US$ 1.2M-2.4M
Registrable Markets
BrazilSaudi ArabiaMexicoVietnam
Process / Sequence / Exact Price
🔒 Sign a CDA to view process / price / customer
Per our compliance red line, before a CDA is signed we do not disclose sequences, full structures, detailed processes, real customer names or exact prices of pre-launch pipelines. Once you raise an RFQ, the system auto-generates a CDA template; upon admin approval the full data room unlocks.